Pfizer (PFE) Total Debt (2009 - 2026)

Pfizer (PFE) has reported Total Debt for 18 consecutive years, with $63.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Debt rose 2.26% year-over-year to $63.2 billion in Q2 2026; TTM through Jun 2026 was $63.2 billion, a 2.26% increase from a year earlier, with the FY2025 full-year figure at $64.8 billion, up 0.69% from the prior year.
• Total Debt was $63.2 billion for Q2 2026 at Pfizer, down from $64.5 billion in the prior quarter.
• Over five years, Total Debt peaked at $72.4 billion in Q4 2023 and troughed at $35.9 billion in Q2 2023.
• A 5-year average of $58.5 billion and a median of $63.8 billion in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt surged 101.28% in 2023 and slipped 11.06% in 2024, its largest moves.
• Over 5 years, Total Debt stood at $35.9 billion in 2022, then jumped by 101.28% to $72.4 billion in 2023, then declined by 11.06% to $64.4 billion in 2024, then gained by 0.69% to $64.8 billion in 2025, then declined by 2.47% to $63.2 billion in 2026.
• The last three Total Debt figures came in at $63.2 billion (Q2 2026), $64.5 billion (Q1 2026), and $64.8 billion (Q4 2025), per Business Quant data.